mRNA再次崛起

8月19日，全球mRNA龙头莫德纳凭借“癌症疫苗”Ⅲ期试验成功落地的利好市值单日暴增445亿美元，引发市场震动，也让这条曾在新冠疫苗研发中大放异彩的技术路线一夜翻红。
On August 19, Moderna—the global leader in mRNA technology—saw its market value soar by $44.5 billion in a single day, following positive readouts from a successful Phase III trial of its cancer vaccine. The surge rattled the markets and catapulted this technology platform—which had already proven its mettle during the COVID-19 vaccine race—back into the limelight overnight.

mRNA疫苗相较于传统技术具备三大核心竞争优势：在生产端，其体外快速量产能力与低成本优势打破了商业化瓶颈；
mRNA vaccines offer three core competitive advantages over conventional approaches: On the manufacturing front, their ability to enable rapid in vitro production at low cost has removed a major barrier to commercial-scale deployment;

在临床端，在保障高免疫激活效果的同时显著提升了安全性；
On the clinical front, they deliver robust immune activation while achieving a markedly improved safety profile;

在战略端，其极高的抗原设计灵活性赋予了疗法快速应对肿瘤突变的能力，为实现“千人千面”的患者个体化精准定制奠定了坚实的技术基础。
On the strategic front, their extraordinary flexibility in antigen design allows therapeutics to adapt swiftly to tumor mutations—laying a strong technological groundwork for truly personalized precision medicine, tailored to each patient's unique profile.